Valion Bio names Thomas Jensen board chair
Bitget2026/10/05 12:40Valion Bio named Thomas H. Jensen as board chair to steer development of Entolimod for acute radiation syndrome. Jensen is CEO and a director of Nasdaq-listed Allarity Therapeutics with more than 20 years of biotech and oncology experience. At Allarity, he led a strategic refocus around lead asset stenoparib, streamlined operations, cut costs, advanced a Phase 2 ovarian cancer program. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief on October 05, 2026, and is solely responsible for the information contained therein.
- Valion Bio named Thomas H. Jensen as board chair to steer development of Entolimod for acute radiation syndrome.
- Jensen is CEO and a director of Nasdaq-listed Allarity Therapeutics with more than 20 years of biotech and oncology experience.
- At Allarity, he led a strategic refocus around lead asset stenoparib, streamlined operations, cut costs, advanced a Phase 2 ovarian cancer program.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
About 700,000 BTC have flowed out of exchanges in the past year.
Korean retail investors shift to the US in Q3: Sold over 5.5 trillion won of Korean stocks, purchased more than 10 trillion won of US stocks
In the third quarter, Korean retail investors made net purchases of US stocks worth approximately 10.15 trillion won, marking a complete reversal from the previous pattern in the first half of the year, when they made net purchases of nearly 100 trillion won in KOSPI stocks. In September alone, the sell-off amount reached as high as 14.2 trillion won. Analysts attribute this shift to a combination of factors: a sharp decline in KOSPI at high levels, the continued strength of the US stock market driven by AI themes, and the appreciation of the Korean won reducing currency exchange costs.
Crypto prices
More
